Identification and characterization of in vitro and in vivo fidarestat metabolites: Toxicity and efficacy evaluation of metabolites-Reference-Cited by-同舟云学术

Identification and characterization of in vitro and in vivo fidarestat metabolites: Toxicity and efficacy evaluation of metabolites

Published:2021-01-06 Issue:2 Volume:56 Page:
ISSN:1076-5174
Container-title:Journal of Mass Spectrometry
language:en
Short-container-title:J Mass Spectrom

Author:

Borkar Roshan M.¹²^ORCID,Gajji Shankar¹,Mohammed Soheb A.³,Srivastava Mithul³,Reddy Velma Ganga⁴,Jala Aishwarya²^ORCID,Asthana Shailendra³,Kamal Ahmed⁴,Banerjee Sanjay K.³⁵^ORCID,Ragampeta Srinivas¹^ORCID

Affiliation:

1. Analytical Chemistry Division CSIR‐Indian Institute of Chemical Technology Hyderabad 500007 India

2. Department of Pharmaceutical Analysis National Institute of Pharmaceutical Education and Research (NIPER) Guwahati Changsari 781101 India

3. Non‐Communicable Diseases Group Translational Health Science and Technology Institute (THSTI) Faridabad 121001 India

4. Department of Organic Synthesis & Process Chemistry CSIR‐Indian Institute of Chemical Technology Hyderabad 500007 India

5. Department of Biotechnology National Institute of Pharmaceutical Education and Research (NIPER) Guwahati Changsari 781101 India

Publisher

Wiley

Subject

Spectroscopy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jms.4694

Reference26 articles.

2. Biochemistry and molecular cell biology of diabetic complications

3. Advanced glycation end products (AGEs) co‐localize with AGE receptors in the retinal vasculature of diabetic and of AGE‐infused rats;Stitt AW;Am J Pathol,1997

4. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy.

5. Fidarestat (SNK-860), a potent aldose reductase inhibitor, normalizes the elevated sorbitol accumulation in erythrocytes of diabetic patients